March 12, 2024

SAVINGS OFFER FOR THE EVERSENSE E3 CGM EXTENDED TO COVER UNLIMITED NUMBER OF SYSTEMS

February 12, 2024

MEDICARE COVERAGE SIGNIFICANTLY EXPANDED FOR THE EVERSENSE E3 CGM SYSTEM

January 02, 2024

Senseonics Holdings, Inc. Announces Business Updates

November 09, 2023

Senseonics Holdings, Inc. Reports Third Quarter 2023 Financial Results

November 09, 2023

Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference

October 30, 2023

Senseonics Holdings, Inc Schedules Third Quarter 2023 Earnings Release and Conference Call for November 9, 2023 at 4:30 p.m. Eastern Time

October 09, 2023

Ascensia Diabetes Care and Senseonics Announce ‘The CGM for Real Life’ Campaign to Raise Awareness of How Long-Term Eversense E3 Empowers People with Diabetes

September 26, 2023

Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

September 14, 2023

Senseonics Holdings, Inc. to Participate in the Gilmartin Group Emerging Growth Company Showcase

September 11, 2023

Senseonics Holdings, Inc. Enters Into $50 Million Loan Facility With Hercules Capital

August 10, 2023

Senseonics Holdings, Inc. Reports Second Quarter 2023 Financial Results

July 27, 2023

Senseonics Holdings, Inc. Schedules Second Quarter 2023 Earnings Release and Conference Call for August 10, 2023 at 4:30 p.m. Eastern Time

July 05, 2023

Senseonics Announces Equity Grants To Employees Under Inducement Plan

June 26, 2023

New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions

June 02, 2023

Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes

May 26, 2023

Senseonics to Participate in the Jefferies Healthcare Conference

May 09, 2023

Senseonics Holdings, Inc. Reports First Quarter 2023 Financial Results

April 27, 2023

Senseonics Holdings, Inc. Schedules First Quarter 2023 Earnings Release and Conference Call for May 9, 2023, at 4:30 p.m. Eastern Time

April 24, 2023

ASCENSIA DIABETES CARE MARKS ONE-YEAR ANNIVERSARY OF US EVERSENSE E3 CGM LAUNCH WITH COMMERCIAL UPDATE AND INNOVATION OUTLOOK

April 18, 2023

Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial

April 05, 2023

Senseonics Announces Equity Grants To Employees Under Inducement Plan

February 17, 2023

Senseonics Holdings, Inc. and PHC Holdings Corporation To Host Joint Eversense CGM Virtual Analyst and Investor Event on March 15, 2023

January 05, 2023

Senseonics Announces Equity Grants To Employees Under Inducement Plan

November 09, 2022

Senseonics to Present at the Stifel 2022 Healthcare Conference

November 08, 2022

Senseonics Holdings, Inc. Reports Third Quarter 2022 Financial Results

November 03, 2022

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)

November 03, 2022

Senseonics and Ascensia Announce a Collaboration with the Nurse Practitioner Group Designed to Expand Patient Access by Providing In-Office and At-Home Insertion Options for Eversense® E3 Continuous Glucose Monitoring System (CGM)

October 25, 2022

Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call for November 8, 2022, at 4:30 p.m. Eastern Time

October 06, 2022

Senseonics Announces Equity Grants To Employees Under Inducement Plan

September 07, 2022

Senseonics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

September 01, 2022

Senseonics Announces CFO Transition

August 17, 2022

Senseonics to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase

August 09, 2022

Senseonics Holdings, Inc. Reports Second Quarter 2022 Financial Results

August 03, 2022

Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem

July 26, 2022

Senseonics Holdings, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 9, 2022, at 4:30 p.m. Eastern Time

July 05, 2022

Senseonics Announces Equity Grants To Employees Under Inducement Plan

June 16, 2022

Senseonics Announces CE Mark Approval of the Eversense E3 Continuous Glucose Monitoring System

May 26, 2022

Senseonics to Participate in the Jefferies Healthcare Conference

May 16, 2022

Senseonics to Participate in the H.C. Wainwright Global Investment Conference

May 10, 2022

Senseonics Holdings, Inc. Reports First Quarter 2022 Financial Results

April 26, 2022

Senseonics Holdings, Inc. Schedules First Quarter 2022 Earnings Release and Conference Call for May 10, 2022, at 4:30 p.m. Eastern Time

April 06, 2022

Senseonics Announces the First Patient Implant of the Eversense E3 CGM System in the U.S.

April 01, 2022

Senseonics Announces Equity Grants to Employees Under Inducement Plan

March 01, 2022

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

February 15, 2022

Senseonics Holdings, Inc. Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for March 1, 2022, at 4:30 p.m. Eastern Time

February 14, 2022

ASCENSIA DIABETES CARE ANNOUNCES FDA APPROVAL OF THE EVERSENSE E3 CONTINUOUS GLUCOSE MONITORING SYSTEM FOR USE FOR UP TO 6 MONTHS

February 11, 2022

Senseonics Announces FDA Approval of the Eversense® E3 Continuous Glucose Monitoring System for Use for Up to 6 months; Provides 2022 Business Outlook

January 05, 2022

Senseonics Announces Equity Grants To Employees Under Inducement Plan

January 04, 2022

Senseonics Announces Business Updates

December 21, 2021

Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe